Literature DB >> 21474674

The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver.

Ashley T Martino1, Masataka Suzuki, David M Markusic, Irene Zolotukhin, Renee C Ryals, Babak Moghimi, Hildegund C J Ertl, Daniel A Muruve, Brendan Lee, Roland W Herzog.   

Abstract

Although adeno-associated viral (AAV) vectors have been successfully used in hepatic gene transfer for treatment of hemophilia and other diseases in animals, adaptive immune responses blocked long-term transgene expression in patients on administration of single-stranded AAV serotype-2 vector. More efficient vectors have been developed using alternate capsids and self-complimentary (sc) genomes. This study investigated their effects on the innate immune profile on hepatic gene transfer to mice. A mild and transient up-regulation of myeloid differentiation primary response gene (88), TLR9, TNF-α, monocyte chemotactic protein-1, IFN-γ inducible protein-10, and IFN-α/β expression in the liver was found after single-stranded AAV vector administration, regardless of the capsid sequence. In contrast, scAAV vectors induced higher increases of these transcripts, upregulated additional proinflammatory genes, and increased circulating IL-6. Neutrophil, macrophage, and natural killer cell liver infiltrates were substantially higher on injection of scAAV. Some but not all of these responses were Kupffer cell dependent. Independent of the capsid or expression cassette, scAAV vectors induced dose-dependent innate responses by signaling through TLR9. Increased innate responses to scAAV correlated with stronger adaptive immune responses against capsid (but not against the transgene product). However, these could be blunted by transient inhibition of TLR9.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21474674      PMCID: PMC3123017          DOI: 10.1182/blood-2010-10-314518

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield.

Authors:  S Zolotukhin; B J Byrne; E Mason; I Zolotukhin; M Potter; K Chesnut; C Summerford; R J Samulski; N Muzyczka
Journal:  Gene Ther       Date:  1999-06       Impact factor: 5.250

2.  The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors.

Authors:  A Lieber; C Y He; L Meuse; D Schowalter; I Kirillova; B Winther; M A Kay
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition.

Authors:  S Bauer; C J Kirschning; H Häcker; V Redecke; S Hausmann; S Akira; H Wagner; G B Lipford
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

4.  Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells.

Authors:  Laura L Stunz; Petar Lenert; David Peckham; Ae-Kyung Yi; Sokol Haxhinasto; Ming Chang; Arthur M Krieg; Robert F Ashman
Journal:  Eur J Immunol       Date:  2002-05       Impact factor: 5.532

Review 5.  Intracellular trafficking of adeno-associated viral vectors.

Authors:  W Ding; L Zhang; Z Yan; J F Engelhardt
Journal:  Gene Ther       Date:  2005-06       Impact factor: 5.250

6.  Identification of mouse AAV capsid-specific CD8+ T cell epitopes.

Authors:  Denise E Sabatino; Federico Mingozzi; Daniel J Hui; Haifeng Chen; Peter Colosi; Hildegund C J Ertl; Katherine A High
Journal:  Mol Ther       Date:  2005-11-02       Impact factor: 11.454

7.  Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors.

Authors:  Vincenzo Cerullo; Michael P Seiler; Viraj Mane; Nicola Brunetti-Pierri; Christian Clarke; Terry K Bertin; John R Rodgers; Brendan Lee
Journal:  Mol Ther       Date:  2007-02       Impact factor: 11.454

8.  Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.

Authors:  Federico Mingozzi; Yi-Lin Liu; Eric Dobrzynski; Antje Kaufhold; Jian Hua Liu; YuQin Wang; Valder R Arruda; Katherine A High; Roland W Herzog
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

9.  Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo.

Authors:  Z Wang; H-I Ma; J Li; L Sun; J Zhang; X Xiao
Journal:  Gene Ther       Date:  2003-12       Impact factor: 5.250

10.  Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis.

Authors:  D D Taub; T J Sayers; C R Carter; J R Ortaldo
Journal:  J Immunol       Date:  1995-10-15       Impact factor: 5.422

View more
  113 in total

Review 1.  Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges.

Authors:  Deepak Raj; Andrew M Davidoff; Amit C Nathwani
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

2.  Adeno-associated virus activates an innate immune response in normal human cells but not in osteosarcoma cells.

Authors:  Leila N Laredj; Peter Beard
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

3.  Covert warfare against the immune system: decoy capsids, stealth genomes, and suppressors.

Authors:  Brad E Hoffman; Roland W Herzog
Journal:  Mol Ther       Date:  2013-09       Impact factor: 11.454

4.  Moving forward toward a cure for hemophilia B.

Authors:  Thierry VandenDriessche; Marinee K Chuah
Journal:  Mol Ther       Date:  2015-05       Impact factor: 11.454

5.  TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy.

Authors:  Scott N Ashley; Suryanarayan Somanathan; April R Giles; James M Wilson
Journal:  Cell Immunol       Date:  2019-10-26       Impact factor: 4.868

6.  Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.

Authors:  Ashley T Martino; Etiena Basner-Tschakarjan; David M Markusic; Jonathan D Finn; Christian Hinderer; Shangzhen Zhou; David A Ostrov; Arun Srivastava; Hildegund C J Ertl; Cox Terhorst; Katherine A High; Federico Mingozzi; Roland W Herzog
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

7.  Cell Cycle-Dependent Expression of Adeno-Associated Virus 2 (AAV2) Rep in Coinfections with Herpes Simplex Virus 1 (HSV-1) Gives Rise to a Mosaic of Cells Replicating either AAV2 or HSV-1.

Authors:  Francesca D Franzoso; Michael Seyffert; Rebecca Vogel; Artur Yakimovich; Bruna de Andrade Pereira; Anita F Meier; Sereina O Sutter; Kurt Tobler; Bernd Vogt; Urs F Greber; Hildegard Büning; Mathias Ackermann; Cornel Fraefel
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

8.  Recombinant adeno-associated virus vectors in the treatment of rare diseases.

Authors:  Eric Hastie; R Jude Samulski
Journal:  Expert Opin Orphan Drugs       Date:  2015-05-15       Impact factor: 0.694

Review 9.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Authors:  Dominic J Gessler; Guangping Gao
Journal:  Methods Mol Biol       Date:  2016

10.  Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo.

Authors:  Dwaipayan Sen; Rupali A Gadkari; Govindarajan Sudha; Nishanth Gabriel; Yesupatham Sathish Kumar; Ruchita Selot; Rekha Samuel; Sumathi Rajalingam; V Ramya; Sukesh C Nair; Narayanaswamy Srinivasan; Alok Srivastava; Giridhara R Jayandharan
Journal:  Hum Gene Ther Methods       Date:  2013-04       Impact factor: 2.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.